Brief: Lipocine Announces Completion Of Enrollment And Dosing In Phase 3 Trial Of LPCN 1154 In Postpartum Depression
20/01/2026 13:02
Jan 20 (Reuters) - Lipocine Inc LPCN.O: LIPOCINE ANNOUNCES COMPLETION OF ENROLLMENT AND DOSING IN PHASE 3 TRIAL OF LPCN 1154 IN POSTPARTUM DEPRESSION (PPD) LIPOCINE INC - TOPLINE RESULTS EXPECTED EARLY Q2 2026 Source text: ID:nPn6zPhKTa Further company coverage: LPCN.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lipocine
See all newsUS STOCKS ON THE MOVE-Halozyme, Moderna, Merck
U.S. STOCKS ON THE MOVE-Halozyme, BKV, AppFolio
U.S. STOCKS ON THE MOVE-Hecla Mining, XPO, Lipocine
Lipocine surges after Canada approves co's testosterone replacement therapy
Brief: Lipocine Announces Health Canada Approval Of Tlando For Testosterone Replacement Therapy